¼¼°èÀÇ ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ½ÃÀå
Optical Genome Mapping
»óǰÄÚµå : 1788234
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 208 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¿ÉƼÄà À¯Àüü ¸ÅÇÎ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 6¾ï 1,520¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 3,960¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 6¾ï 1,520¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 28.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ¼­ºñ½º´Â CAGR 28.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3¾ï 3,260¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ¼Ò¸ðǰ¡¤½Ã¾à ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 29.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,670¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 26.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ½ÃÀåÀº 2024³â¿¡´Â 3,670¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 26.5%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 9,290¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 25.7%¿Í 24.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 19.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿ÉƼÄà À¯Àüü ¸ÅÇÎÀÌ ±âÁ¸ À¯Àüü ºÐ¼®À» ÆÄ±«ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

¿ÉƼÄà À¯Àüü ¸ÅÇÎ(OGM)Àº ±âÁ¸ ½ÃÄö½Ì ±â¼ú·Î´Â ³õÄ¡±â ½¬¿î ±¸Á¶Àû º¯ÀÌ(SV)¸¦ ½Äº°ÇÏ´Â µ¥ ÀÖ¾î Àü·Ê ¾ø´Â ÇØ»óµµ¿Í Á¤È®µµ¸¦ Á¦°øÇÔÀ¸·Î½á À¯Àüü ¿¬±¸¿Í Áø´Ü¿¡ Çõ½ÅÀ» °¡Á®¿À´Â Á¸Àç·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®±â(NGS)´Â À¯ÀüüÇп¡ Çõ¸íÀ» °¡Á®¿ÔÁö¸¸, »ðÀÔ, °á½Ç, ¿ªÀ§, ÀüÁÂ¿Í °°Àº ´ë±Ô¸ð À¯Àüü Àç¹è¿­À» °ËÃâÇÏ´Â µ¥´Â ¿©ÀüÈ÷ ÇѰ谡 ÀÖ½À´Ï´Ù. ÃÊÀå¼â DNA ºÐÀÚ¸¦ ÀÌ¿ëÇϰí À̸¦ ³ª³ëä³Î ¾î·¹ÀÌ·Î À̹Ì¡ÇÔÀ¸·Î½á OGMÀº ÁõÆøÀ̳ª ´ÜÆíÈ­ ¾øÀÌ À¯Àüü ÀüüÀÇ ±¸Á¶Àû Ư¡À» ½Ç½Ã°£À¸·Î °¡½ÃÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ´É·ÂÀº º¹ÀâÇÑ À¯Àü¼º Áúȯ, Ç÷¾× ¾Ç¼º Á¾¾ç, °íÇü Á¾¾ç, Èñ±ÍÁúȯ µî ±¸Á¶Àû ÀÌ»óÀ» ÀÌÇØÇÏ´Â °ÍÀÌ Áø´Ü ¹× Ä¡·á °èȹ¿¡ ÇʼöÀûÀÎ Áúȯ¿¡¼­ ƯÈ÷ À¯¿ëÇÏ°Ô È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡¼­ Á¾ÇÕÀûÀÎ À¯Àüü ÇÁ·ÎÆÄÀϸµ¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÏ°í ºñ¿ë È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁü¿¡ µû¶ó, Çаè, ÀÓ»ó ½ÇÇè½Ç, »ý¸í°øÇÐ ±â¾÷µéÀº OGMÀ» º¸¿ÏÀû ¶Ç´Â ÁÖ¿ä µµ±¸·Î äÅÃÇϰí ÀÖ½À´Ï´Ù. OGMÀº ±âÁ¸ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ÆÄÀÌÇÁ¶óÀΰú ¿øÈ°ÇÏ°Ô ÅëÇÕµÉ ¼ö ÀÖÀ¸¸ç, ½ÃÄö½Ì¸¸À¸·Î´Â ¾òÀ» ¼ö ¾ø´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÔÀ¸·Î½á ¿¬±¸ ¿öÅ©Ç÷ο츦 À籸¼ºÇϰí, ¹ø¿ª ¹× ÀÓ»ó ÀÀ¿ë ºÐ¾ß¿¡¼­ À¯Àüü µ¥ÀÌÅÍÀÇ À¯¿ë¼ºÀ» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº OGMÀÇ ¼º´É°ú Á¢±Ù¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

¿ÉƼÄà À¯Àüü ¸ÅÇÎÀÇ »óȲÀº OGM Ç÷§ÆûÀ» ´õ¿í °ß°íÇϰí, »ç¿ëÇϱ⠽±°í, ´õ ±¤¹üÀ§ÇÑ ÀÀ¿ë ºÐ¾ß¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â Áß¿äÇÑ ±â¼ú ¹ßÀüÀ¸·Î ºü¸£°Ô º¯È­Çϰí ÀÖ½À´Ï´Ù. ³ª³ë ä³Î Ĩ ¼³°è ¹× »ùÇà Á¶Á¦ ÀÚµ¿È­ÀÇ °³¼±Àº ÀÛ¾÷ ½Ã°£À» ´ÜÃàÇϰí 󸮷®À» Çâ»ó½ÃÄÑ OGMÀ» ´ë·® ÀÓ»ó ½ÇÇè½Ç°ú Çмú ¿¬±¸¼¾ÅÍ ¸ðµÎ¿¡ º¸´Ù ½Ç¿ëÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. AI¿Í ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀÇ ÅëÇÕÀº ±¸Á¶Àû º¯ÇüÀÇ È£Ãâ°ú ÇØ¼®ÀÇ Á¤È®µµ¸¦ ³ôÀ̰í, ÀÎÀû ¿À·ù¸¦ ÃÖ¼ÒÈ­ÇÏ¿© º¸´Ù ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. µ¿½Ã¿¡ µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ Å¬¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº ¿¬±¸ÀÚ¿Í ÀÓ»óÀÇÀÇ Çù¾÷À» °£¼ÒÈ­Çϰí À¯Àüü Áö½Ä¿¡ ´ëÇÑ ¾ÈÀüÇÑ ½Ç½Ã°£ ¾×¼¼½º¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. OGM Ç÷§ÆûÀ» ºÐ»êÇü ¹× POC(Point-of-Care) ȯ°æ¿¡ ÀûÇÕÇÏ°Ô ¸¸µå´Â °ÍÀ» ¸ñÇ¥·Î ¼ÒÇüÈ­ ¹× ÈÞ´ëÈ­ ÀÛ¾÷µµ ÁøÇà ÁßÀÔ´Ï´Ù. Ç÷¾×, °ñ¼ö, °íÇüÁ¶Á÷ µî ´Ù¾çÇÑ À¯ÇüÀÇ ½Ã·á¿¡¼­ º¹ÀâÇÑ Ã³¸® ¾øÀÌ ÃʰíºÐÀÚ·® DNA¸¦ ºÐ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ ÀÌ ¹æ¹ýÀÇ À¯¿ë¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çü±¤ Ç¥Áö È­ÇÐ ¹× ±¤ÇÐ °ËÃâÀÇ ¹ßÀüÀ¸·Î ½ÅÈ£ÀÇ ¼±¸íµµ°¡ Çâ»óµÇ¾î ´ë±Ô¸ð À¯ÀüüÀÇ ±¸Á¶Àû ¿ä¼Ò¸¦ º¸´Ù Á¤È®ÇÏ°Ô ¸ÅÇÎÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÊ¿¡ µû¶ó µµÀÔ À庮ÀÌ ³·¾ÆÁú »Ó¸¸ ¾Æ´Ï¶ó, À¯Àüü ºÐ¼®ÀÇ ¼Óµµ, È®À强, ¹Î°¨µµ¿¡ ´ëÇÑ »õ·Î¿î ±âÁØÀÌ È®¸³µÇ°í ÀÖ½À´Ï´Ù.

¾î¶² ÃÖÁ¾ ¿ëµµ ºÎ¹®ÀÌ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÀ¿ë ºÐ¾ßÀÇ °æ°è¸¦ ³ÐÈ÷°í Àִ°¡?

±¤À¯Àüü ¸ÅÇο¡ ´ëÇÑ ¼ö¿ä´Â ´Ù¾çÇÑ ÃÖÁ¾ »ç¿ë ºÐ¾ß¿¡¼­ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, °¢±â ´Ù¸£Áö¸¸ Áߺ¹µÇ´Â ¸ñÀûÀ¸·Î ÀÌ ±â¼úÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó Áø´Ü¿¡¼­ Ç÷¾×ÇÐ ¹× Á¾¾çÇÐÀÌ °¡Àå Ȱ¹ßÇÑ ºÐ¾ßÀ̸ç, OGMÀº ¹éÇ÷º´, ¸²ÇÁÁ¾, °íÇü Á¾¾ç°ú °ü·ÃµÈ ±¸Á¶Àû µ¹¿¬º¯À̸¦ ¹ß°ßÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. »ý½ÄÀ¯ÀüÇп¡¼­ OGMÀº ÀÌÇüü³ª Ä«ÇÇ ¼ö º¯ÀÌ¿Í °°Àº ¿°»öü ÀÌ»ó¿¡ ´ëÇÑ »êÀü ¹× »êÈÄ Áø´Ü¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. Çмú¿¬±¸±â°ü°ú À¯Àüü¼¾Å͵µ º¹ÀâÇÑ À¯Àüü ±¸Á¶¿Í À¯ÀüÀÚ Á¶Àý ³×Æ®¿öÅ©¸¦ ¹àÇô³»´Â ´É·ÂÀ¸·Î ÀÎÇØ Áý´Ü¿¬±¸, ÁøÈ­»ý¹°ÇÐ, ±â´ÉÀ¯ÀüüÇп¡ OGMÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ºÐ¾ß¿¡¼­ OGMÀº ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ½Äº°°ú Àΰø ¼¼Æ÷ÁÖ¿¡¼­ À¯ÀüÀû ºÒ¾ÈÁ¤¼ºÀ» Ư¼ºÈ­ÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖÀ¸¸ç, ƯÈ÷ ½Å¾à°³¹ß ÆÄÀÌÇÁ¶óÀο¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ³ó¾÷À¯ÀüüÇÐ ¿ª½Ã »õ·Î¿î ºÐ¾ß·Î, OGMÀº ÀÛ¹° °³·®°ú ÇüÁú ¼±ÅÃÀ» À§ÇØ ½Ä¹° À¯Àüü ¸ÅÇο¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ ÀÌ¿ë »ç·Ê°¡ ±¤¹üÀ§ÇÏ°Ô È®´ëµÊ¿¡ µû¶ó ´Ù¾çÇÑ ½Ã·á À¯Çü°ú µ¥ÀÌÅÍ ºÐ¼® ȯ°æ¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ¹ü¿ë¼º ³ôÀº OGM Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú Á¦°ø¾÷ü¿Í ÀÇ·á±â°üÀÇ Çù¾÷Àº °ËÁõ ¿¬±¸¿Í ÀÓ»ó äÅÃÀ» ÃËÁøÇÏ°í ½ÃÀåÀ» ³Î¸® ¼ö¿ëÇÏ´Â ¹æÇâÀ¸·Î ³ª¾Æ°¡°í ÀÖ½À´Ï´Ù.

¿ÉƼÄà À¯Àüü ¸ÅÇÎ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

±¤ÇÐ À¯Àüü ¸ÅÇÎ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÃÖÁ¾»ç¿ëÀÚ ¼ö¿ä, À¯Àüü ¿¬±¸ ¹× Áø´ÜÀÇ ¿ì¼±¼øÀ§ º¯È­¿Í °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ Á¾¾çÇÐ ¹× Èñ±ÍÁúȯ Áø´Ü¿¡¼­ °íÇØ»óµµ ±¸Á¶Àû µ¹¿¬º¯ÀÌ °ËÃâ¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °Ë»ç½ÇÀÌ OGMÀ» ¿öÅ©Ç÷ο쿡 ÅëÇÕÇÏ´Â °ÍÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ´ë±Ô¸ð À¯Àüü º¯È­ÀÇ ½Äº°¿¡ ÀÖ¾î ªÀº ¸®µå ½ÃÄö½ÌÀÇ ÇѰè´Â ƯÈ÷ Á¾ÇÕÀûÀÎ À¯Àüü ±¸Á¶ ÇÁ·ÎÆÄÀϸµÀÌ ÇʼöÀûÀÎ °æ¿ì OGM¿¡ ´ëÇÑ º¸¿ÏÀûÀÎ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­ Àåºñ, °³¼±µÈ ³ª³ëä³Î ¾î·¹ÀÌ ¼³°è, È®Àå °¡´ÉÇÑ µ¥ÀÌÅÍ ºÐ¼® Ç÷§ÆûÀÇ ¹ßÀüÀ¸·Î OGMÀº ´õ¿í »ç¿ëÇϱ⠽±°í ¿î¿µ È¿À²¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. À¯Àüü ÀÇÇÐ ¹× Á¤¹Ð Á¾¾çÇп¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡, ƯÈ÷ Á¤ºÎ ¹× ¹Î°£ ÀÇ·á ÀÌ´Ï¼ÅÆ¼ºêÀÇ ÀÚ±Ý Áö¿ø Áõ°¡·Î ÀÎÇØ º´¿ø ¹× Àü¹® ¿¬±¸¼ÒÀÇ °í°´ ±â¹ÝÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. OGM°ú ¸ÖƼ¿À¹Í½º Á¢±Ù¹ý ¹× ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º »ýŰè¿ÍÀÇ ÅëÇÕÀº ¿¬±¸¿Í ÀÓ»ó ¸ðµÎ¿¡¼­ ¿£µåÅõ¿£µå ½Ã½ºÅÛ Â÷¿øÀÇ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ´Â ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. Áö±Ý±îÁö Áø´ÜÀÌ ºÒ°¡´ÉÇß´ø »ç·Ê¸¦ ÇØ°áÇÏ´Â OGMÀÇ °íÀ¯ÇÑ °¡Ä¡¿¡ ´ëÇÑ ÀÓ»óÀÇ¿Í À¯ÀüÇÐÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ äÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ½ÅÈï ½ÃÀå¿¡¼­´Â Èñ±ÍÁúȯÀÇ ¹ß°ß°ú ºñ¿ë È¿À²ÀûÀÎ ¾Ï Áø´ÜÀ» °³¼±ÇÏ·Á´Â ¿òÁ÷ÀÓÀÌ ºñ¿°±â¼­¿­ºÐ¼® ±â¹Ý À¯Àüü Åø¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´©ÀûµÈ ÃßÁø·ÂÀ¸·Î ÀÎÇØ ¿ÉƼÄà À¯Àüü ¸ÅÇÎÀº Á¤¹Ð Áø´Ü°ú À¯Àüü ¹ß°ßÀÇ ´ÙÀ½ ½Ã´ë¿¡ Áß¿äÇÑ ¿øµ¿·ÂÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¿ÉƼÄà À¯Àüü ¸ÅÇÎ ¼­ºñ½º, ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ¼Ò¸ðǰ¡¤½Ã¾à, ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ¼ÒÇÁÆ®¿þ¾î, ¿ÉƼÄà À¯Àüü ¸ÅÇÎ ±â±â), ±â¼ú À¯Çü(±¸Á¶ º¯ÀÌ °ËÃâ, À¯Àüü ¾î¼Àºí¸®, ¹Ì»ý¹°ÁÖ Å¸ÀÌÇÎ, ±âŸ ±â¼ú), ¿ëµµ(¿¬±¸, Áø´Ü), ÃÖÁ¾ ¿ëµµ(Çмú¿¬±¸±â°ü, º´¿ø¡¤ÀÓ»ó ¿¬±¸¼Ò, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¡¤Á¦¾à ±â¾÷)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Optical Genome Mapping Market to Reach US$615.2 Million by 2030

The global market for Optical Genome Mapping estimated at US$139.6 Million in the year 2024, is expected to reach US$615.2 Million by 2030, growing at a CAGR of 28.0% over the analysis period 2024-2030. Optical Genome Mapping Services, one of the segments analyzed in the report, is expected to record a 28.9% CAGR and reach US$332.6 Million by the end of the analysis period. Growth in the Optical Genome Mapping Consumables & Reagents segment is estimated at 29.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$36.7 Million While China is Forecast to Grow at 26.5% CAGR

The Optical Genome Mapping market in the U.S. is estimated at US$36.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$92.9 Million by the year 2030 trailing a CAGR of 26.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 25.7% and 24.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 19.3% CAGR.

Global Optical Genome Mapping Market - Key Trends & Drivers Summarized

Why Is Optical Genome Mapping Disrupting Conventional Genomic Analysis?

Optical Genome Mapping (OGM) is emerging as a transformative force in genomic research and diagnostics, offering unprecedented resolution and accuracy in identifying structural variations (SVs) that are often missed by traditional sequencing technologies. While next-generation sequencing (NGS) has revolutionized genomics, it remains limited in detecting large-scale genomic rearrangements such as insertions, deletions, inversions, and translocations-areas where OGM excels. By utilizing ultra-long DNA molecules and imaging them in nanochannel arrays, OGM allows for real-time visualization of structural features across the entire genome without amplification or fragmentation. This capability is proving especially valuable in complex genetic disorders, hematological malignancies, solid tumors, and rare diseases, where understanding structural anomalies is critical for diagnosis and treatment planning. The growing need for comprehensive genomic profiling in personalized medicine, coupled with the demand for cost-effective and scalable solutions, is pushing academic institutions, clinical laboratories, and biotech companies to adopt OGM as a complementary or even primary tool. Its ability to integrate seamlessly with existing bioinformatics pipelines while offering insights that sequencing alone cannot provide is reshaping research workflows and expanding the utility of genomic data in translational and clinical applications.

How Are Technological Advances Enhancing the Performance and Accessibility of OGM?

The Optical Genome Mapping landscape is being rapidly reshaped by significant technological advancements that are making the platform more robust, user-friendly, and accessible across a broader range of applications. Improvements in nanochannel chip design and automated sample preparation are reducing hands-on time and increasing throughput, making OGM more practical for both high-volume clinical labs and academic research centers. The integration of AI and machine learning algorithms is enhancing the accuracy of structural variant calling and interpretation, minimizing human error and allowing for more reliable diagnostics. At the same time, cloud-based platforms for data analysis are simplifying collaboration between researchers and clinicians, enabling secure, real-time access to genomic insights. Miniaturization and portability efforts are also underway, with the goal of making OGM platforms suitable for decentralized and point-of-care environments. The ability to analyze ultra-high molecular weight DNA from various sample types-blood, bone marrow, solid tissue-without complex processing is expanding the method’s utility. Moreover, advancements in fluorescent labeling chemistries and optical detection are improving signal clarity, allowing for more precise mapping of structural elements across large genomes. As these innovations continue, they are not only lowering the barriers to adoption but also setting new standards in speed, scalability, and sensitivity for genomic analysis.

What End-Use Sectors Are Driving Demand and Expanding Application Frontiers?

The demand for Optical Genome Mapping is accelerating across a diverse set of end-use sectors, each leveraging the technology for distinct yet overlapping purposes. In clinical diagnostics, hematology and oncology are the most active domains, with OGM being used to uncover structural variants associated with leukemias, lymphomas, and solid tumors-many of which are undetectable through conventional karyotyping or chromosomal microarrays. In reproductive genetics, OGM is gaining traction for pre- and post-natal diagnostics of chromosomal abnormalities such as aneuploidies and copy number variations. Academic research institutions and genome centers are also adopting OGM for population studies, evolutionary biology, and functional genomics, due to its ability to uncover complex genomic architectures and gene regulatory networks. In the biopharmaceutical sector, OGM is being integrated into drug discovery pipelines, especially in biomarker identification and characterization of genetic instability in engineered cell lines. Agricultural genomics is another emerging area, where OGM is used to map plant genomes for crop improvement and trait selection. These broad and expanding use cases are driving demand for versatile OGM platforms that can operate across different sample types and data analysis environments. Furthermore, collaborations between technology providers and healthcare institutions are catalyzing validation studies and clinical adoption, pushing the market toward widespread acceptance.

What Forces Are Powering the Growth of the Optical Genome Mapping Market?

The growth in the Optical Genome Mapping market is driven by several factors related to technological evolution, end-user demands, and shifts in genomic research and diagnostic priorities. The growing need for high-resolution structural variant detection, particularly in oncology and rare disease diagnostics, is pushing laboratories to integrate OGM into their workflows. The limitations of short-read sequencing in identifying large-scale genomic alterations are creating a complementary demand for OGM, especially in cases where comprehensive genome structural profiling is essential. Advancements in automated instrumentation, improved nanochannel array designs, and scalable data analysis platforms are making OGM more user-friendly and operationally efficient. Increasing funding for genomic medicine and precision oncology, especially from government and private healthcare initiatives, is expanding the customer base among hospitals and specialty labs. The integration of OGM with multi-omics approaches and bioinformatics ecosystems is creating opportunities for end-to-end, systems-level insights in both research and clinical domains. Rising awareness among clinicians and geneticists about the unique value of OGM in solving previously undiagnosable cases is accelerating adoption. In emerging markets, the push for improved rare disease detection and cost-effective cancer diagnostics is encouraging investment in non-sequencing-based genomic tools. These cumulative drivers are establishing Optical Genome Mapping as a critical enabler in the next era of precision diagnostics and genomic discovery.

SCOPE OF STUDY:

The report analyzes the Optical Genome Mapping market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Optical Genome Mapping Services, Optical Genome Mapping Consumables & Reagents, Optical Genome Mapping Software, Optical Genome Mapping Instruments); Technique (Structural Variant Detection Technique, Genome Assembly Technique, Microbial Strain Typing Technique, Other Techniques); Application (Research Application, Diagnostics Application); End-Use (Academic Research Institutes End-Use, Hospitals & Clinical Laboratories End-Use, Biotechnology & Pharmaceutical Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â